Literature DB >> 21175649

Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment.

Pierre Brissot1, Simon Ball, Diana Rofail, Helena Cannon, Vivian Wu Jin.   

Abstract

BACKGROUND: Hereditary hemochromatosis (HH) is a genetic disorder resulting in increased accumulation of dietary iron. It is associated with various clinical complications such as liver cirrhosis and diabetes. The aim of this study was to explore patients' experiences of living with HH, the diagnosis process, and phlebotomy treatment. STUDY DESIGN AND METHODS: An online survey was developed and completed by a total of 210 HH patients across the United States (n = 70), France (n = 50), Ireland (n = 40), and the United Kingdom (n = 50).
RESULTS: Of the 210 patients, 30% were induction patients, 49% were maintenance patients, and 22% had never received phlebotomy. The most common route to diagnosis was by chance (42%), although most patients (87%) reported experiencing symptoms they now associated with HH at the time of diagnosis. Fatigue (60%) and joint pain (50%) were the most frequently reported current symptoms. While 87% of patients felt that treatment with phlebotomy was "quite worthwhile" or "very worthwhile," 52% of induction patients and 37% of maintenance patients experienced side effects "always" or "most of the time" after phlebotomy and 16% of patients would "definitely" or "probably" decide not to receive phlebotomy if alternative options were available.
CONCLUSION: Diagnosis of HH is likely made late in many patients and subsequent phlebotomy treatment, while considered worthwhile by most, leads to concerns over side effects and inconvenience, often impacting patients' lives. Greater efforts to promote awareness of the disease and reduce the treatment burden associated with phlebotomy are required to improve detection and management of this disease.
© 2010 American Association of Blood Banks.

Entities:  

Mesh:

Year:  2010        PMID: 21175649     DOI: 10.1111/j.1537-2995.2010.02997.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  9 in total

Review 1.  Oral nucleic acid therapy using multicompartmental delivery systems.

Authors:  Husain Attarwala; Murui Han; Jonghan Kim; Mansoor Amiji
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

Review 2.  Understanding the Potential and Risk of Bacterial Siderophores in Cancer.

Authors:  Valentina Pita-Grisanti; Kaylin Chasser; Trevor Sobol; Zobeida Cruz-Monserrate
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

3.  Mechanistic basis of the inhibition of SLC11/NRAMP-mediated metal ion transport by bis-isothiourea substituted compounds.

Authors:  Cristina Manatschal; Jonai Pujol-Giménez; Marion Poirier; Jean-Louis Reymond; Matthias A Hediger; Raimund Dutzler
Journal:  Elife       Date:  2019-12-05       Impact factor: 8.140

4.  Renal clearable nanochelators for iron overload therapy.

Authors:  Homan Kang; Murui Han; Jie Xue; Yoonji Baek; JuOae Chang; Shuang Hu; HaYoung Nam; Min Joo Jo; Georges El Fakhri; Michael P Hutchens; Hak Soo Choi; Jonghan Kim
Journal:  Nat Commun       Date:  2019-11-13       Impact factor: 14.919

5.  Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators.

Authors:  Seung Hun Park; Richard S Kim; Wesley R Stiles; Minjoo Jo; Lingxue Zeng; Sunghoon Rho; Yoonji Baek; Jonghan Kim; Moon Suk Kim; Homan Kang; Hak Soo Choi
Journal:  Adv Sci (Weinh)       Date:  2022-03-27       Impact factor: 17.521

6.  SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1.

Authors:  Sandro Altamura; Ute Schaeper; Sibylle Dames; Kathrin Löffler; Mona Eisermann; Christian Frauendorf; Katja Müdder; Joana Neves; Martina U Muckenthaler
Journal:  Hemasphere       Date:  2019-10-01

7.  Quality of Life Scores Remained Different among the Genotypic Groups of Patients with Suspected Hemochromatosis, Even after Treatment Period.

Authors:  Luis Alfredo Utria Acevedo; Aline Morgan Alvarenga; Paula Fernanda Silva Fonseca; Nathália Kozikas da Silva; Rodolfo Delfini Cançado; Flavio Augusto Naoum; Carla Luana Dinardo; Alexandre Costa Pereira; Pierre Brissot; Paulo Caleb Junior Lima Santos
Journal:  Genes (Basel)       Date:  2022-01-10       Impact factor: 4.096

8.  The effect of a natural polyphenol supplement on iron absorption in adults with hereditary hemochromatosis.

Authors:  Simone Buerkli; Laura Salvioni; Natalie Koller; Christophe Zeder; Maria José Teles; Graça Porto; Jana Helena Habermann; Irina Léa Dubach; Florence Vallelian; Beat M Frey; Diego Moretti; Jeannine Baumgartner; Michael B Zimmermann
Journal:  Eur J Nutr       Date:  2022-03-23       Impact factor: 4.865

9.  A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.

Authors:  Eva Rombout-Sestrienkova; Bjorn Winkens; Marian van Kraaij; Cees Th B M van Deursen; Mirian C H Janssen; Alexander M J Rennings; Dorothea Evers; Jean-Louis Kerkhoffs; Ad Masclee; Ger H Koek
Journal:  J Clin Apher       Date:  2020-12-24       Impact factor: 2.821

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.